Table: Peptidream -2023 group results (IFRS)
Feb 14 (Reuters)-
Peptidream Inc.
CONSOLIDATED FINANCIAL HIGHLIGHTS
(in billions of yen unless specified)
Year ended Year ended Year to NEXT
Dec 31, 2023 Dec 31, 2022 Dec 31, 2024 YEAR
LATEST YEAR-AGO COMPANY COMPANY
RESULTS RESULT FORECAST H1 FORECAST
Sales 28.71 26.85 35.00
(+6.9 pct) (+185.0 pct) (+21.9 pct)
Operating 6.77 8.98 10.50
(-24.6 pct) (+120.8 pct) (+55.0 pct)
Pretax 4.35 6.65 10.20
(-34.6 pct) (+74.9 pct) (+134.3 pct)
Net 3.04 7.55 7.30
(-59.8 pct) (+193.6 pct) (+140.5 pct)
EPS Basic 23.41 yen 58.19 yen
EPS Diluted 23.38 yen 58.14 yen
Ann Div NIL NIL NIL
-Q2 Div NIL NIL NIL
-Q4 Div NIL NIL NIL
NOTE - Peptidream Inc..
(Figures are reported based on international accounting rules (IFRS).)
If there is no Q1 or Q3 dividend, Q2 will in most cases correspond to the first-half
dividend and Q4 to the second-half dividend announced before a new corporate law in
2006 allowed companies to pay and report dividends on a quarterly basis.
*Net - represents Net profit attributable to owners of the parent company.
To see Company Overview page, click reuters://REALTIME/verb=CompanyData/ric=4587.T
Recent news on PeptiDream
See all newsTable: Peptidream 6-MTH group results (IFRS)
Brief: Peptidream Inc. - Initiation Of Phase 1 Clinical Trial By Novartis Marks Milestone For Peptidream
Brief: PeptiDream Announces First Dosing Of 64cu-Pd-29,875 In Gastric Cancer Patients
Table: Peptidream -Q1 group results (IFRS)
Brief: Peptidream Announces The Initiation Of Phase 1 Clinical Trial By Its Collaboration Partner